Overview of 4DMedical's Quarterly Activity Report and Appendix 4C for Q2 FY2024

4DMedical Limited (ASX: $4DX) has reported a 60% increase in operating revenue for 1H FY2024, reaching $0.8m. The company acquired US-based Imbio, a leader in lung and heart AI-powered diagnostic products, and signed a Teaming Agreement with Philips to expand the commercialization of XV Technology within the U.S. Department of Veterans Affairs. The company's cash balance as at 31 December 2023 was $47.8m.

Executive Commentary on Recent Developments

4DMedical MD/CEO and Founder Andreas Fouras stated, '4DMedical enters 2024 with considerable momentum with a transformational acquisition and an impressive number of significant commercial milestones accomplished over the last quarter, the most recent of which is the signing of the Teaming Agreement with Philips.'

Summary of Quarterly Activity Report and Outlook

4DMedical's acquisition of Imbio aligns with its growth strategy, providing additional lung diagnostic tools and accelerating the commercialization of XV Technology in the U.S. The company's strong cash position and successful capital raise indicate a positive outlook for future developments. The strategic collaboration with Philips presents significant opportunities to advance solutions for toxic exposure and lung screening, particularly within the VA. Furthermore, the CMS approval for reimbursement and expanded distribution in the U.S. demonstrate the company's progress in commercialization efforts and its commitment to enhancing respiratory health solutions.